Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification by Powe, Desmond G et al.
Open Access
Available online http://breast-cancer-research.com/content/11/6/R90
Page 1 of 15
(page number not for citation purposes)
Vol 11 No 6 Research article
Investigating AP-2 and YY1 protein expression as a cause of high 
HER2 gene transcription in breast cancers with discordant HER2 
gene amplification
Desmond G Powe1, Gulfareen Akhtar2, Hany Onsy Habashy2,3, Tarek Abdel-Fatah2, 
Emad A Rakha1, Andrew R Green2 and Ian O Ellis2
1Department of Cellular Pathology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Derby Road, Nottingham NG7 2UH, UK
2Department of Pathology, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust and University of Nottingham, Derby 
Road, Nottingham NG7 2UH, UK
3Department of Histopathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
Corresponding author: Ian O Ellis, ian.ellis@nottingham.ac.uk
Received: 7 Jul 2009 Revisions requested: 11 Aug 2009 Revisions received: 20 Nov 2009 Accepted: 21 Dec 2009 Published: 21 Dec 2009
Breast Cancer Research 2009, 11:R90 (doi:10.1186/bcr2461)
This article is online at: http://breast-cancer-research.com/content/11/6/R90
© 2009 Powe et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Candidacy for anti-HER2 adjuvant therapy in
breast cancer is assessed using tumour HER2 status but
recently it has been proposed that the transcription factors AP-
2α and YY1 may cause Her2 protein overexpression
independently of gene amplification.
Methods We characterised AP-2α/β, AP-2α and YY1 with
HER2 gene and protein expression, other relevant biomarkers,
and clinical outcome using tissue microarrays (TMAs) and
immunohistochemistry in a large (n = 1,176) clinically annotated
series of early stage operable breast cancer. The associations
and prognostic independence of AP-2 and YY1 was assessed
in all patients and an oestrogen receptor negative subgroup.
Results Nuclear expression of AP-2α/β, AP-2α and YY1 was
detected in 23%, 44% and 33% of cases respectively. AP-2α/
β significantly correlated with YY1 and both markers were
increased in luminal oestrogen receptor (ER) positive tumours of
small size and low grade but only AP-2α/β correlated with good
prognosis breast cancer specific survival and disease free
interval (BCSS and DFI). These characteristics were lost in
oestrogen receptor negative patients. AP-2α also correlated
with luminal-type tumours but not with YY1 expression or good
prognosis. AP-2α and YY1 showed a significant correlation with
Her2 protein expression and in addition, YY1 correlated with
HER2 gene expression. Discordant HER2 gene and protein
expression was identified in six cases (0.71% of the study
group) with four of these showing AP-2α but absence of AP-2α/
β and YY1 expression.
Conclusions AP-2α/β and YY1 are markers of good prognosis
principally due to their association with oestrogen receptor but
are not independent predictors. Discordant HER2 protein/gene
expression is a rare event that is not always explained by the
actions of AP-2 and YY1.
Introduction
HER2 amplification occurs in approximately 20% breast can-
cer patients and is generally associated with poor prognosis
compared to HER2 negative counterparts [1,2]. Over-expres-
sion of HER2 is generally seen in high grade breast cancers
and is associated with aggressive tumour growth characteris-
tics including increased proliferation [3], enhanced tumori-
genicity [4] and metastatic potential [5]. These adverse
properties can be ameliorated by blockade of HER2 protein
with the humanised monoclonal antibody, trastuzumab, and is
targeted at patients that show HER2 amplification [6]. Further-
more, it has been recently shown that HER2 positive node
negative patients with low grade breast cancer also benefit
AP-2: activator protein-2; AR: androgen receptor; AT: adjuvant therapy; Bcl2: B-cell lymphoma-2; BCSS: breast cancer specific survival; BRCA1: 
breast cancer gene 1; CBP: CREB binding protein; CI: confidence interval; CK: cytokeratin; DFI: Disease free interval; DM: distant metastasis; EGFR: 
epidermal growth factor receptor; ER: oestrogen receptor; FOXA1: Forkhead box gene A1; HDAC: histone-deacetylase; IHC: immunohistochemistry; 
Mib1: antibody that recognises the proliferation antigen Ki67; PgR: progesterone receptor; TMA: tissue microarray; YY1: Yin Yang protein-1.Breast Cancer Research    Vol 11 No 6    Powe et al.
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from trastuzumab therapy [7] but its increased use has to be
balanced by potential toxicity [8].
Over-expression of HER2 protein is usually accounted for by
gene amplification. Detection of HER2 protein is routinely per-
formed using immunohistochemistry (IHC) with visual assess-
ment where a score of 3+ assumes HER2 oncogene
amplification [9]. In equivocal cases scoring 2+ gene status is
assessed using the gold standard fluorescent in situ hybridi-
sation or chromogenic in situ hybridisation techniques [10].
Recent evidence has suggested that increased transcription
of HER2 protein can occur due to activation of the HER2 pro-
moter by transcriptional factors, including activating protein-2
(AP-2) and Yin Yang protein-1 (YY1) [11]. The AP-2 family
contains five homologous 50 kDa proteins encoded by individ-
ual genes, which regulate transcription through interaction
with several nuclear factors associated with specific genetic
programs [12]. AP-2 proteins have multi-functional roles,
including control of normal cell growth and differentiation, and
also carcinogenesis including breast cancer [13]. At least four
binding sites have been identified for AP-2 in the promoter of
the HER2 gene [13,14] and some studies have shown a cor-
relation between the expression of AP-2 with HER2 over-
expression in breast cancer cell lines [12-15] suggesting that
AP-2 and its neutralisation could be a means of down regulat-
ing HER2 [15].
The Yin Yang protein (YY1) is a conserved zinc-finger DNA-
binding phosphoprotein transcriptional factor that regulates
initiation, activation and repression of transcription for a
number of genes connected with cell growth, development
and differentiation [16-18]. YY1 has been reported to regulate
the oncogene retinoblastoma protein Rb [19] and CBP [20]
and furthermore, binds to the ubiquitous alpha component
present in replication-dependent histones. Because of its role
in chromatin remodelling, involving interaction with histone-
deacetylase (HDAC) [21], YY1 may be associated with global
gene expression and has received interest as a potential ther-
apeutic target in human cancer [22-24]. Moreover, YY1 has
recently been identified as a new cofactor stimulating AP-2
transcriptional activity [25].
In the current study, we used a large (n = 1,176) and well char-
acterised series of patients with early stage invasive breast
cancer to investigate the frequency of discordant HER2 gene
and protein levels and to evaluate the role of AP-2α/β, AP-2α
and YY1 in these tumours. The implication of amplification-
independent HER2 overexpression is that patients with equiv-
ocal Her2 protein expression (Her2 score 2+) might be denied
clinical anti-HER2 adjuvant therapy (AT). In addition, the clin-
icopathological value of AP-2 and YY1 in breast cancer was
assessed in view of the previous conflicting reports and its
proposed role as a possible therapeutic target in breast
cancer.
Materials and methods
This study was approved by the Nottingham Research Ethics
Committee 2 under the title 'Development of a molecular
genetic classification of breast cancer'. Production of the
study and analysis of the data was independent of the funding
bodies associated with this project.
Patient selection
Tissue microarrays (TMAs) containing 1,176 primary operable
breast carcinoma cases derived from the Nottingham Tenovus
Primary Breast Carcinoma Series were used as previously
reported [26]. The cohort comprised women aged 70 years or
less, who presented between 1986 and 1999. This well-char-
acterized resource contains information on patients' clinical
and pathological data including histologic tumour type, pri-
mary tumour size, lymph node status, histologic grade, and
data on other breast cancer relevant biomarkers. Patients
within the good prognostic group (Nottingham Prognostic
Index (NPI) ≤ 3.4) did not receive adjuvant therapy (AT). Hor-
monal therapy (HT) was prescribed to patients with ER-α+
tumours and NPI scores of >3.4 (moderate and poor prognos-
tic groups). Pre-menopausal patients within the moderate and
poor prognostic groups were candidates for CMF (Cyclo-
phosphamide, Methotrexate, and 5-Flourouracil) chemother-
apy. Conversely, postmenopausal patients with moderate or
poor NPI and ER-α+ were offered HT, while ER-α-patients
received CMF if fit. Survival data including survival time, dis-
ease-free interval (DFI) and development of loco-regional and
distant metastases (DM) were maintained on a prospective
basis. Median follow up was 124 months (range 1 to 233).
Breast cancer specific survival (BCSS) was defined as the
time (in months) from the date of the primary surgical treatment
to the time of death from breast cancer. DFI was defined as the
interval (in months) from the date of the primary surgical treat-
ment to the first loco-regional or distant metastasis.
Immunohistochemistry
Two antibodies were selected for detection of AP-2; a mouse
monoclonal antibody was used to recognise the AP-2α/β iso-
forms (Abcam, Cambs, UK; clone A6/2/2; dilution 1:700), and
a polyclonal rabbit antibody recognising only the AP-2α iso-
form (Active Motif, Carlsbad, USA; dilution 1:100) was also
used. Both AP-2 antibodies and the anti-YY1 antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA; clone H-10; dilu-
tion 1:100) were optimised for immunohistochemistry (IHC)
on full face excisional breast tissue sections to assess homo-
geneity of staining. Subsequently, a 13-slide series (n = 1,176
cases) comprising 4 μm thick formalin fixed paraffin embed-
ded breast cancer tissue TMAs were immunostained using
microwave antigen retrieval in 0.01 M pH 6.0 citrate buffer
(AP2 antibodies) or 0.01 M pH 8.0 EDTA (YY1). An indirect
labelled streptavidin avidin biotin technique (LSAB) technique
with diaminobenzidine (DAB) chromogen was performed
using a DakoCytomation Techmate 500 Plus (DakoCytoma-
tion, Cambridge, UK) automatic immunostainer as previouslyAvailable online http://breast-cancer-research.com/content/11/6/R90
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described [27]. Negative controls were performed by omitting
the primary antibody and substitution with diluent. Subse-
quently, immunostained sections were counterstained in hae-
matoxylin. After immunohistochemistry, cases were assessed
using the H-score (histochemical score) to measure staining
intensity and the percentage of stained tumour cells corre-
sponding to each intensity [28]. The cases were scored with-
out knowledge of the patient outcome by three of the authors
(DGP, GA, HOH) and the resulting data were categorised
using thresholds set by reference to a frequency distribution
histogram plotted for AP-2 and YY1 proteins and by to the
median H-scores. The median H-score of 100 or greater was
categorised as positive for AP-2 and YY1 staining. In addition,
AP-2 and YY1 were characterised in breast cancer by investi-
gating their association with other breast tumour relevant
markers using cut-off thresholds as previously described
[26,29].
Her2 scoring was performed on replicate 4 μm thick breast
cancer TMAs using a Ventana BenchMark immunostainer
(Roche Diagnostics, Surrey, UK) with the Pathway HER2/neu
(4B5) rabbit monoclonal antibody according to the manufac-
turer's instructions. Breast carcinomas were microscopically
assessed to determine the level of Her2 protein expression
using the manufacturers threshold criteria based on the rec-
ommendations of the American Society of Clinical Oncolo-
gists and the College of American Pathologists [2]. Intensity
and pattern of membrane staining seen in at least 10% of cells
was scored: 1+ = non-amplified, 3+ = gene amplification, and
2+ = equivocal result and warranted further investigation of
amplification status using an INFORM HER2/neu DNA probe
with a silver in situ hybridisation (SISH) technique according
to the manufacturers instructions (Roche Diagnostics). Sec-
tions were counterstained in haematoxylin and all reagents
were supplied by Roche Diagnostics. The sections were ini-
tially screened using a Nikon E600 microscope (Nikon, Surrey,
UK) fitted with an ×20 and ×40 objective lens. The number of
silver signals corresponding to the gene copy number of
HER2 and chromosome 17 (Chr17) was counted in malignant
breast epithelial cells only using a quantitative method. For
each tumour, a HER2/Chr17 ratio was determined from the
average number of signals located in at least 20 cells from rep-
licate sections. Cases that failed to show signal in normal cells
adjacent to neoplastic tissue were excluded. Cases with a
HER2/Chr17 ratio less than1.8 were deemed non-amplified
whereas ratio's greater than 2.2 were designated as amplified.
Statistical analysis
Statistical analysis was performed using SPSS 15.0 statistical
software (SPSS Inc, Chicago, IL, USA). Association between
AP-2 and YY1 protein expression with different clinicopatho-
logical parameters was evaluated in the entire patient series
and in an ER negative patient cohort only using the Pearson
Chi-square or Fisher's exact test. Standard cut-off values for
the different biomarkers, needed to determine categorical
scores before statistical analysis, were the same as those pub-
lished in previous studies [26,27,30]. Cumulative survival
probabilities were estimated using the Kaplan-Meier method
with a log rank test to assess significance between different
survival rates. Patients that died due to causes other than
breast cancer were censored during survival analysis. Multivar-
iate analysis for survival was performed using the Cox propor-
tional hazard regression model. Each variable was assessed in
univariate analysis as a continuous and categorical variable
and the two models were compared using an appropriate like-
lihood ratio test. Hazard ratios (HR) and 95% confidence inter-
vals (95% CI) were estimated for each variable. All tests were
two-sided with a 95% CI and significant P value was <0.05.
Results
Characterisation of AP-2 and YY1 positive tumours and 
their association with tumour-relevant biomarkers in the 
entire patient series
AP-2 and YY1 immunostaining showed predominant nuclear
localisation with variable cytoplasmic staining (Figure 1).
AP-2α/β isoforms: Informative data were obtained on 1,176
tissue cores of which 22.8% showed AP-2 expression. AP-
2α/β and YY1 expression was positively correlated (χ =
167.5, P < 0.001).
High AP-2α/β nuclear expression was significantly increased
in small (≤ 1.5 cm) compared to large tumours (P < 0.001) of
low tumour grade (P < 0.001). Positive AP-2α/β expression
was more frequent in lobular breast cancer (BC) compared to
negative cases (17.1% compared to 8.3%, respectively)
showing good NPI (P < 0.001) and reduced vascular invasion
(P = 0.036). Patients' characteristics are summarized in Table
1.
AP-2α/β nuclear staining positively correlated with the hormo-
nal receptors [oestrogen receptor-α (ER) (P < 0.001), proges-
terone receptor (PgR) (P  < 0.001), the luminal-associated
marker CK19 (P = 0.007), and with Bcl2 (P = 0.042). Signif-
icant inverse correlations were observed between AP-2 and
HER4 (P = 0.001), Mib1 (P = 0.005), EGFR (P = 0.045), and
the basal markers CK5/6 (P = 0.006) and CK14 (P = 0.011).
Details of the associations with other biomarkers are shown in
Table 2.
AP-2α isoform: An antibody recognising AP-2α isoform was
selected to allow comparison with a previous study reported
by Allouche et al [11]. The pattern of staining using the AP-2α
isoform-specific antibody was similar to that seen using the
AP-2α/β antibody but no significant association was seen with
YY1 (χ = 3.297, P < 0.069). Informative data were obtained
on up to 942 cases with 44% showing positive staining. AP-
2α expression showed no significant association with patient
age, tumour size, grade, lymph node stage, prognosis using
NPI, formation of distant metastases, tumour recurrence orBreast Cancer Research    Vol 11 No 6    Powe et al.
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vascular invasion. The frequency of positive AP-2α expression
was two-fold more prevalent in medullary BC compared to
negative cases. Patients' characteristics are summarized in
Table 1.
AP-2α nuclear staining positively correlated with the hormonal
receptor ER (P = 0.02), and the luminal-associated marker
CK19 (P  = 0.016). Significant inverse correlations were
observed between AP-2α and HER4 (P = 0.003), Mib1 (P <
0.001), and the basal marker CK5/6 (P = 0.006). Details of
the association between with other biomarkers are shown in
Table 2.
YY1: Informative data were obtained on 1,159 tissue cores
with 33.3% being positively categorized for YY1 expression.
High YY1 nuclear expression was significantly increased in
small (≤ 1.5 cm) (P = 0.028) low grade (P < 0.001) tumours
with good NPI (P < 0.001). Positive YY1 expression was more
frequent in lobular and tubular BC compared to negative
cases. No significant association was found with respect to
patient age, lymph node stage, formation of distant metas-
tases, tumour recurrence or vascular invasion. Patients' char-
acteristics are summarized in Table 3.
Positive YY1 nuclear staining was associated with ER (P <
0.001), PgR (P < 0.001), CK19 (P = 0.037), and Bcl2 (P <
0.001). Significant inverse correlations were found between
YY1 and HER4 (P < 0.001), CK5/6 (P = 0.015), CK14 (P =
0.023), p53 (P = 0.002), and MIB1 (P = 0.035). Details of the
associations with other biomarkers are shown in Table 4.
Characterisation of AP-2 and YY1 positive tumours and 
their association with tumour-relevant biomarkers in ER-
negative patients
Due to the significant correlation found between AP2 with ER
and the predicted good clinical outcome in hormonal-positive
patients, these associations were investigated in ER-negative
cases to test the dependency on ER status.
AP-2α/β isoforms: AP-2α/β protein expression was studied
in 309 ER negative patients and showed no significant asso-
ciation with either tumour size, lymph node stage, histological
grade, development of metastasis, vascular invasion, tumour
type, menopausal status, PgR, CK19, HER3, HER4, E-cad-
herin, EGFR, CK5/6, CK14, p53 or Bcl2 (data not shown).
However, AP-2α/β protein expression showed significant
inverse associations with the proliferation marker Mib1 (χ2 =
4.671, P = 0.031) and good prognosis measured using NPI
(χ2 = 6.428, P = 0.04).
AP-2α isoform: AP-2α/β protein expression was studied in
266 ER negative patients and showed no significant associa-
tion with tumour size, lymph node stage, histological grade,
prognosis (NPI), development of metastasis, vascular invasion,
tumour type, menopausal status, PgR, HER3, E-cadherin,
EGFR, CK14, p53 or Bcl2 (data not shown). However, AP-2α
Figure 1
AP-2 α/β (a, c, e) and YY1 (b, d, f) immunostaining AP-2 α/β (a, c, e) and YY1 (b, d, f) immunostaining. Tumour nuclear staining varied from homogeneously strong (a, b) to a mixed (c, d) pattern but 
was intense in normal glandular tissue (e, f) (arrow) (×20 magnification).Available online http://breast-cancer-research.com/content/11/6/R90
Page 5 of 15
(page number not for citation purposes)
Table 1
Patients' characteristics showing AP-2 protein expression
AP-2 (α and β isoforms) AP-2 (α isoform)
Variable Positive (%) Negative (%) χ 2
(P-value)
Positive (%) Negative (%) χ 2
(P-value)
Patients age
<40 16
(6.0)
69
(7.6)
2.381 (0.497) 45
(8.7)
35
(8.3)
0.225 (0.973)
40-50 69 (25.7) 244 (26.9) 160 (30.8) 134 (31.7)
51-60 79 (29.5) 285 (31.4) 169 (32.6) 133 (31.4)
>60 104 (38.8) 310 (34.1) 145 (27.9) 121 (28.6)
Primary tumour size
≤ 1.5 cm 112 (41.6) 274 (30.3) 12.125 (<0.001) 252
(48.4)
215 (51.6) 0.943
(0.332)
>1.5 cm 157 (58.4) 631 (69.7) 269 (51.6) 202 (48.4)
Lymph node Stage
1 177 (65.8) 554 (61.3) 5.382 (0.068) 331 (63.5) 249 (59.6) 1.949 (0.377)
2 78
(29.0)
263 (29.1) 143 (27.4) 132 (31.6)
3 14
(5.2)
87
(9.6)
47
(9.0)
37
(8.8)
Grade
1 60
(22.3)
137 (15.2) 43.672 (<0.001) 66 (12.7) 73
(17.5)
4.476 (0.107)
2 124 (46.1) 274 (30.3) 160 (30.7) 126 (30.2)
3 85
(31.6)
493 (54.5) 295 (56.6) 218 (52.3)
NPI
Poor 25
(9.3)
224 (24.8) 35.333 (<0.001) 85
(16.3)
84
(20.1)
3.574
(0.167)
Moderate 130 (48.3) 517 (57.1) 303 (58.2) 219 (52.4)
Good 114 (42.4) 164 (18.1) 133 (25.5) 115 (27.5)
Development of Distant Metastasis
No 193 (73.1) 611 (68.0) 2.528 (0.112) 341 (66.1) 302 (71.7) 3.436 (0.064)
Positive 71
(26.9)
288 (32.0) 175 (33.9) 119 (28.3)
Development of Recurrence
No 165 (62.5) 504 (56.4) 3.069 (0.08) 294 (57.8) 248 (60.6) 1.969 (0.374)
Positive 99
(37.5)
389 (43.6) 215 (42.2) 161 (39.4)
Vascular invasion
No 168 (63.2) 495 (55.0) 6.674 (0.036) 286 (55.5) 220 (52.4) 0.949 (0.622)
Probable 21
(7.9)
109 (12.1) 61
(11.8)
52
(12.4)
Definite 77
(28.9)
296 (32.9) 168 (32.6) 148 (35.2)
Tumour type
Ductal/NST 129 (49.0) 551 (61.5) 29.22 (<0.001) 326 (63.9) 252 (60.3) 15.31 (0.032)Breast Cancer Research    Vol 11 No 6    Powe et al.
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protein expression showed significant positive association
with CK19 (χ2 = 4.982, P = 0.026) and HER4 (χ2 = 5.885, P
= 0.015), and a significant negative association with the basal
marker CK5/6 (χ2 = 5.569, P = 0.018) and the proliferation
marker Mib1 (χ2 = 8.521, P = 0.004).
Association of AP-2 and YY1 with clinical outcome
The AP-2 and YY1 antibodies were tested using Kaplan Meier
plots to model clinical outcome, and using Cox regression
analysis to determine their ability to predict clinical outcome
measured against tumour size, grade, and lymph node stage.
AP-2α/β isoforms: AP-2α/β expression was significantly
associated with longer breast cancer specific survival (BCSS)
(Log rank (LR) = 7.607, P = 0.006; HR = 1.5 (95% CI = 1.1
to 2.01), P = 0.006; Figure 2) and an increased disease free
interval (DFI) (LR = 9.201, P = 0.002; HR = 1.565 (95%
CI:1.168 to 2.096), P = 0.003; Figure 3) but not for distant
metastasis (DM) formation or tumour recurrence. The AP-2α/
β specific antibody was not found to be an independent pre-
dictor of survival using Cox regression (P  = 0.397; HR =
0.880 (95% CI: 0.654 to 1.184)).
AP-2α isoform: AP-2α showed no significant association with
improved BCSS (χ2 = 0.888, P = 0.346), DFI (χ2 = 1.557, P
= 0.212), DM (χ2 = 1.838, P = 0.175) or tumour recurrence
(χ2 = 0.207, P = 0.649) using Kaplan-Meier modelling. The
AP-2α specific antibody was not found to be an independent
predictor of survival using Cox regression (P = 0.866; HR =
0.978 (95% CI: 0.751 to 1.272)).
YY1: YY1 showed a significant association with improved
BCSS (χ2 = 5.565, P = 0.018; Figure 4) and DFI (χ2 = 6.576,
P = 0.010; Figure 5) but not for DM (χ2 = 2.443, P = 0.118)
or tumour recurrence (χ2 = 0.438, P = 0.508) using Kaplan
Meier modelling. YY1 was not found to be an independent pre-
dictor of survival using Cox regression (P  = 0.866; HR =
0.978 (95% CI:0.751 to 1.272)).
Correlation between HER2 protein and gene expression 
and the role of AP-2 and YY1
AP-2α/β isoform: Her2 protein expression data were availa-
ble for 679 tumour cores expressing AP-2α/β (Figure 6). AP-
2α/β staining was seen in 120/555 (21.6%), 13/34 (38.2%),
5/26 (19.2%), and 13/64 (20.3%) cases scoring 0, 1+, 2+
and 3+ for Her2 membranous staining respectively. Eighteen
of 90 (20.0%) patients with 2+ or 3+ Her2 membrane expres-
sion were AP-2α/β positive. No significant association was
seen between AP-2α/β and Her2 protein staining (Table 5).
HER2 gene amplification showed a highly significant positive
association with Her2 (3+) protein scoring (P < 0.001) and
was detected in 78/702 (11.1%). AP-2α/β staining was
present in 18/78 (23.1%) gene amplified cases but showed
no significant difference compared to the non-amplified
tumours (P = 0.249). Details of the association between AP-
2α/β and HER2 expression are contained in Table 5.
AP-2α isoform: Her2 protein expression data were available
for 631 tumour cores expressing AP-2α and showed a signif-
icant positive association with AP-2α staining (P = 0.032). AP-
2α staining was seen in 31/93 (33.3%), 191/428 (44.6%),
11/28 (39.3%), and 45/64 (54.8%) cases scoring 0, 1+, 2+
and 3+ for Her2 membranous staining respectively. Fifty-six of
110 (50.9%) patients with 2+ or 3+ Her2 membrane expres-
sion were AP-2α positive.
Lobular 45
(17.1)
74
(8.3)
46
(9.0)
35
(8.4)
Tubular and Tubular mixed 61
(23.2)
178 (19.9) 81
(15.9)
90
(21.5)
Medullary 4
(1.5)
29
(3.2)
22
(4.3)
7
(1.7)
Other special types* 8
(3.0)
12
(1.3)
7
(1.4)
7
(1.7)
Mixed** 16
(6.1)
47
(5.2)
26
(5.1)
24
(5.7)
Menopausal status
Premenopausal 103 (38.4) 355 (39.1) 0.038 (0.845) 212 (40.8) 171 (40.4) 0.017 (0.896)
Postmenopausal 165 (61.6) 553 (60.9) 307 (59.2) 252 (59.6)
Two different AP-2 antibodies were used; one recognised AP-2α and β isoforms while the other recognised only the AP-2α isoform. *Includes 
Mucoid, invasive cribriform and invasive papillary carcinoma. **Includes ductal/No special type (NST) mixed with lobular or special types. NPI = 
Nottingham Prognostic Index.
Table 1 (Continued)
Patients' characteristics showing AP-2 protein expressionAvailable online http://breast-cancer-research.com/content/11/6/R90
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Table 2
Association of two AP-2 isoforms with cancer relevant biomarkers
AP-2 (α and β isoforms) AP-2 (α isoform)
Biomarker Negative
(%)
Positive
(%)
χ2 P-value Negative Positive χ2 P-value
ER
Negative 293 (34.6) 45 (18.5) 22.70 <0.001 248 (34.4) 102 (26.0) 5.287 0.02
Positive 555 (65.4) 198 (81.5) 472 (65.6) 291 (74.0)
PgR
Negative 410 (48.3) 72 (30.0) 25.524 <0.001 358 (49.9) 173 (44.0) 0.514 0.473
Positive 438 (51.7) 168 (70.0) 359 (50.1) 220 (56.0)
CK19
Negative 87
(10.0)
11
(4.5)
7.349 0.007 63
(12.6)
31
(7.7)
5.811 0.016
Positive 785 (90.0) 236 (95.5) 436 (87.4) 372 (92.3)
HER3
Negative 77
(10.7)
24 (11.9) 0.222 0.638 40
(9.4)
20
(5.7)
3.730 0.053
Positive 642 (89.3) 178 (88.1) 387 (90.6) 333 (94.3)
HER4
Negative 131 (18.3) 60 (29.1) 11.491 0.001 82
(19.0)
39 (11.3) 8.776 0.003
Positive 586 (81.7) 146 (70.9) 349 (81.0) 307 (88.7)
E-cadherin
Negative 345 (40.5) 85 (34.6) 2.871 0.09 179 (36.3) 142 (35.7) 0.038 0.846
Positive 506 (59.5) 161 (65.4) 314 (63.7) 256 (64.3)
EGFR
Negative 582 (78.9) 182 (85.0) 4.004 0.045 361 (80.6) 286 (78.4) 0.612 0.434
Positive 156 (21.1) 32
(15)
87
(19.4)
79 (21.6)
CK5/6
Negative 713 (81.5) 224 (88.9) 7.65 0.006 399 (79.3) 346 (86.3) 7.457 0.006
Positive 162 (18.5) 28 (11.1) 104 (20.7) 55 (13.7)
CK14
Negative 736 (85.5) 233 (94.0) 6.456 0.011 426 (86.8) 361 (90.9) 3.787 0.052
Positive 125 (14.5) 15
(6.0)
65
(13.2)
36
(9.1)
P53
Negative 620 (72.6) 189 (77.8) 2.62 <0.106 328 (66.8) 294 (74.1) 5.504 0.019
Positive 234 (27.4) 54 (22.2) 163 (33.2) 103 (25.9)
Mib1
Negative 189 (43.0) 76 (56.7) 7.827 0.005 95
(34.2)
100 (50.5) 12.755 <0.001
Positive 251 (57.0) 58 (43.3) 183 (65.8) 98 (49.5)
Bcl2
Negative 43
(12.8)
7
(6.0)
4.139 0.042 18
(9.8)
24 (13.2) 1.044 0.307
Positive 292
(87.2)
110 (94.0) 166 (90.2) 158 (86.8)
ER: oestrogen receptor; PgR: Progesterone receptor; CK-: Cytokeratin; EGFR: epidermal growth factor receptor.Breast Cancer Research    Vol 11 No 6    Powe et al.
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Table 3
Patients' characteristics showing YY1 protein expression
YY1
Variable Positive (%) Negative (%) χ2
(P-value)
Patients age
26 (6.7) 53 (6.9) 1.454
(0.693)
110 (28.5) 196 (25.4)
119 (30.8) 242 (31.3)
131 (33.9) 282 (36.5)
Primary tumour size
≤ 1.5 cm 144 (37.6) 241 (31.1) 4.817
(0.028)
>1.5 cm 239 (62.4) 533 (68.9)
Lymph node Stage
1 234 (61.1) 492 (63.6) 1.982
(0.371)
2 118 (30.8) 209 (27.0)
3 31 (8.1) 72 (9.3)
Grade
1 85 (22.2) 113 (14.6) 46.984 (<0.001)
2 162 (42.3) 220 (28.5)
3 136 (35.5) 440 (56.9)
NPI
Poor 49 (12.8) 193 (24.9) 17.284 (<0.001)
Moderate 195 (50.9) 444 (57.4)
Good 139 (36.3) 137 (17.7)
Development of Distant Metastasis
No 274 (71.5) 521 (68.2) 1.343
(0.246)
Positive 109 (28.5) 243 (31.8)
Development of Recurrence
No 226 (59.2) 435 (57.4) 0.328
(0.567)
Positive 156 (40.8) 323 (42.6)
Vascular invasion
No 232 (60.7) 417 (54.4) 4.45
(0.108)
Probable 37 (9.7) 94 (12.3)
Definite 113 (29.6) 256 (33.4)
Tumour type
Ductal/NST 195 (51.2) 474 (62.3) 29.509
(<0.001)
Lobular 53 (13.9) 59 (7.8)
Tubular and Tubular mixed 99 (26.0) 140 (18.4)
Medullary 5 (1.3) 29 (3.8)
Other special types* 8 (2.1) 11 (1.4)
Mixed** 19 (5) 45 (5.9)
Menopausal status
Premenopausal 160 (41.5) 284 (36.7) 2.417 (0.12)
Postmenopausal 226 (58.5) 489 (63.3)
*Includes Mucoid, invasive cribriform and invasive papillary carcinoma. **Includes ductal/No special type (NST) mixed with lobular or special types. 
NPI = Nottingham Prognostic Index.Available online http://breast-cancer-research.com/content/11/6/R90
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HER2 gene amplification was detected in a total of 63/500
(12.6%) cases with 32 (6.4%) of these expressing AP-2α
staining. No significant association was found between AP-2α
protein expression and HER2 amplification (P = 0.446).
Details of the association between AP-2α/β and HER2
expression are contained in Table 5.
YY1: Her2 protein expression data were available for 666
tumour cores expressing YY1. YY1 staining was seen in 178/
544 (32.7%), 20/33 (60.6%), 7/28 (25.0%), 10/61 (16.4%)
cases scoring 0, 1+, 2+ and 3+ for Her2 membranous stain-
ing respectively, and showed a significant inverse correlation
with Her2 protein expression (P < 0.001). Seventeen of 215
(7.9%) patients with positive YY1 staining showed 2+ or 3+
Her2 membrane expression Table 6.
HER2 gene amplification was detected in 84/609 (13.8%)
cases and showed an inverse correlation with YY1 protein
expression (P = 0.004). 16/84 (19%) YY1-positive cases also
showed HER2 gene amplification. Details of the association
between AP-2 and YY1 with HER2 expression are contained
in Table 6.
Cases showing discordant HER2 protein and gene 
expression and their association with AP-2 and YY1 
expression
HER2 SISH gene data were available for 846 cases with 115/
842 (13.7%) showing amplification and 32/842 (3.8%) cases
showing gene gain. Over-expression (3+) of Her2 protein was
seen in 118 cases but only 2 cases (0.24% total cohort),
equivalent to 2/118 (1.7%) cases, showed an absence of
HER2 gene amplification was seen in just showing (3+) Her2
over-expression. Both cases were AP-2α and AP-2α/β posi-
tive but YY1 negative.
A further 5/842 (0.6%) cases showed (3+) Her2 protein over-
expression in the presence of HER2 gene gain. Two of these
cases were AP-2α positive but AP-2α/β and YY1 negative,
one case was AP-2α and AP-2α/β positive but YY1 negative,
and one case was negative for all three markers.
An additional 4/842 (0.5%) cases showed equivocal (2+)
Her2 protein over-expression in the absence of HER2 gene
amplification. Two of these cases were AP-2α positive but AP-
2α/β and YY1 negative and two cases were negative for all
three markers.
In summary, a total of 6/141 (4.3%) cases showed equivocal
or over-expressed Her2 protein in the absence of HER2 gene
amplification or gain, representing 0.71% of the total patient
cohort.
Discussion
A number of studies have proposed conflicting roles for AP-2
in breast cancer including a tumour suppressor gene (TSG)
Table 4
The association of YY1 protein levels were compared with 
cancer relevant biomarkers in breast tumours
YY1
Biomarker Negative Positive χ2 P-value
ER
Negative 248 (34.4) 64 (17.9) 31.912 <0.001
Positive 472 (65.6) 294 (82.1)
PgR
Negative 358 (49.9) 120 (33.7) 25.343 <0.001
Positive 359 (50.1) 236 (66.3)
CK19
Negative 77 (10.4) 24 (6.6) 4.370 0.037
Positive 661 (89.6) 341 (93.4)
HER3
Negative 68 (11.1) 37 (12.5) 0.388 0.534
Positive 543 (88.9) 258 (87.5)
HER4
Negative 104 (16.9) 85 (28.7) 16.938 <0.001
Positive 511 (83.1) 211 (71.3)
E-cadherin
Negative 294 (40.8) 127 (35.2) 3.170 0.075
Positive 427 (59.2) 234 (64.8)
EGFR
Negative 503 (79.7) 251 (81.0) 0.205 0.651
Positive 128 (20.3) 59 (19.0)
CK5/6
Negative 599 (80.6) 315 (86.5) 5.947 0.015
Positive 144 (19.4) 49 (13.5)
CK14
Negative 623 (85.3) 325 (90.3) 5.183 0.023
Positive 107 (14.7) 35 (9.7)
P53
Negative 508 (70.2) 281 (78.9) 9.318 0.002
Positive 216 (29.8) 75 (21.1)
Mib1
Negative 168 (41.7) 91 (51.1) 4.450 0.035
Positive 235 (58.3) 87 (48.9)
Bcl2
Negative 230 (38.9) 72 (24.3) 18.556 <0.001
Positive 362 (61.1) 224 (75.7)
ER = oestrogen receptor; PgR = Progesterone receptor; CK- = 
Cytokeratin; EGFR = epidermal growth factor receptor.Breast Cancer Research    Vol 11 No 6    Powe et al.
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function [31,32], or more recently and controversially, that of
an oncogene [11]. In the largest study of patients with primary
operable breast cancer to date, we characterised two iso-
forms of the transcription factor AP-2, namely AP-2α/β and
AP-2α, and its cofactor YY1. We found differences between
the AP-2 isoforms that could explain the conflicting roles
reported for AP-2. Importantly, we showed a strong associa-
tion between AP-2α/β expression and the luminal (ER posi-
tive) tumour phenotype that endows these patients with
favourable clinical outcome characterised by prolonged sur-
vival and longer disease free interval. In contrast the associa-
tion between AP-2α and ER is weaker and patients with this
profile do not have such good prognosis, supporting a tumour
suppressor role for AP-2β.
In contrast to luminal breast cancers, HER2 tumours are char-
acterised by an aggressive phenotype and if untreated have a
poor prognosis. However, targeted treatment with the human-
ised monoclonal anti-HER2 antibody, trastuzumab, can signif-
icantly improve a patient's outcome [6,8,9]. It has recently
been proposed that the transcription factor AP-2α and its
cofactor, YY1, can induce HER2 gene transcription independ-
ently of HER2 gene mutation in breast cancer [11]. For this
reason we investigated discordant HER2 gene and protein
expression and the association between the transcription fac-
tors AP-2 and YY1 and their association with HER2 in a large
population of well characterised breast cancer patients. Two
different AP-2 antibodies were used; one was specific for AP-
2α/β isoforms while the other was specific for the AP-2α iso-
form only. We found 23% and 44% patients showed high AP-
2α/β and AP-2α levels, respectively, which is in the general
range (17-42%) [11,32] reported by others. Allouche et al
used a percentage scoring technique and a threshold of
>80% to determine AP-2α and YY1 positivity, but even
though we used a different scoring technique (H-score) with
the same AP-2α antibody, we showed good agreement with
their study in positively categorizing 44% our patients com-
pared to 42% in the study by Allouche et al [11].
Moreover, Allouche et al proposed that AP-2α can induce
Her2 protein expression in patients with absence of HER2
gene amplification because of an observed inverse relation-
ship between breast cancers expressing AP-2α protein and a
positive association with HER2 gene amplification [11]. Our
findings support Allouche in showing a positive correlation
between AP-2α and Her-2 membranous expression but we
did not find a significant association between AP-2α and
HER2 gene amplification, or between AP-2α and YY1. Simi-
Figure 2
Kaplan-Meier model comparing breast cancer specific survival in breast cancer patients with AP-2 α/β protein expression Kaplan-Meier model comparing breast cancer specific survival in breast cancer patients with AP-2 α/β protein expression.Available online http://breast-cancer-research.com/content/11/6/R90
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larly, no significant association was identified between AP-2α/
β expression and HER2 gene and protein expression. Some of
these differences appear to be explained by differences in the
patient populations analyzed in Allouche's and our study as
only 56% of our study cohort scored 2+/3+ by Her2 IHC com-
pared to 83% identified by Allouche et al. Furthermore,
Allouche et al observed 15/55 (27.3%) patients with strong
(3+) Her3 IHC staining and 2/15 (13.3%) with absence of
HER2 amplification but with strong AP-2α/YY1 expression. In
our study, we report 16.2% of our patients had (3+) Her2 IHC
staining and just 2/82 (2.4%) of these showed absence of
gene amplification; both cases expressed AP-2α but not YY1.
Our findings suggest that discordant HER2 expression is a
rare event in 3+ Her2 cases and while AP-2α may have a role,
further studies are needed to validate this and to study the role
of YY1. However, discordant HER2 patients face a possible
dilemma in their treatment because the moderate to high levels
of HER2 protein expression support candidacy for anti-HER2
AT but contradictory (negative) HER2 gene expression sug-
gest AT refusal. Further studies are needed to assess anti-
HER2 AT in this patient group.
Although both AP-2α and AP-2α/β specific antibodies
detected tumours with a significant association with ER, the
association was stronger when using the AP-2α/β marker as
indicated by the strong association with the hormonal receptor
PgR and luminal marker CK19. A possible conclusion result-
ing from this observation is that the AP-2β isoform shows a
stronger association with ER. YY1 also showed similar fea-
tures in associating with luminal type cancers and showed a
significant association with AP-2α/β. Consequently, along
with others [31-33] we found a significant association
between AP-2α/β and good prognosis but this relationship
was lost in our ER-negative patient subgroup. ER blockade in
ER+ breast cancers reduces AP-2α gene expression but at
the same time increases AP-2γ expression [34] and in addi-
tion, it has been reported that AP-2α/γ can increase the activ-
ity of the ERβ promoter resulting in its increased gene
expression [35]. Whereas there is good evidence favouring a
TSG function for AP-2α, it has been proposed that AP-2γ is an
oncogene affecting multiple growth signalling pathways [36]
and functions as an independent predictor of poor survival in
patients with breast cancer[37].
In the current study, although the association between nuclear
AP-2 expression and good clinical outcome might be
explained by its association with ER, there is evidence sug-
gesting that AP-2 influences important biological pathways. In
Figure 3
Kaplan-Meier model comparing disease free interval in breast cancer patients showing AP-2α/β protein expression Kaplan-Meier model comparing disease free interval in breast cancer patients showing AP-2α/β protein expression.Breast Cancer Research    Vol 11 No 6    Powe et al.
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Figure 4
Kaplan-Meier model comparing breast cancer specific survival in breast cancer patients showing YY1 protein expression Kaplan-Meier model comparing breast cancer specific survival in breast cancer patients showing YY1 protein expression.
Figure 5
Kaplan-Meier model comparing disease free interval in breast cancer patients showing YY1 protein expression Kaplan-Meier model comparing disease free interval in breast cancer patients showing YY1 protein expression.
one study, patients with AP-2α positive tumours showed pro-
longed survival and an increased disease free interval possibly
explained by the activity of AP-2α in inducing growth arrest by
activation of the cell cycle inhibitor p21WAF1 [38]. Our find-
ings are supportive in showing decreased cell proliferation
using the marker Mib1. In vivo colonic cell studies suggest
AP-2 up-regulates the over-expression of the cell adhesion
molecule E-cadherin needed for cell cohesion, while simulta-
neously decreasing transcription of the matrix metalloprotein-
ase (MMP)-9 [39] involved in migration of tumour cells throughAvailable online http://breast-cancer-research.com/content/11/6/R90
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Figure 6
AP-2α/β, YY1 and Her-2 immunostaining AP-2α/β, YY1 and Her-2 immunostaining. Weak AP-2α/β (a) and YY1 (b) expression but strong (3+) Her-2 staining (c) is seen in this tumour. 
(×20 magnification)
Table 5
Association between AP-2 protein expression and HER-2 status
AP-2 (α and β isoforms) AP-2 (α isoform)
Negative Positive χ2
P-value Negative Positive χ2
P-value
HER-2
Gene
Expression
Normal 459 (76.4%) 142 (23.6%) 2.782 0.249 217
(53.6%)
188 (46.4%) 2.664 0.446
Amplified 60 (76.9%) 18 (23.1%) 31 (49.2%) 32 (50.8%)
Gain 21 (91.3%) 2 (8.7%) 15 (46.9%) 17
(53.1%)
HER-2
Protein
Expression
0 435 (78.4%) 120 (21.6%) 5.427 0.143 237
(55.4%)
191
(44.6%)
8.550 0.032
1+ 21 (61.8%) 13 (38.2%) 62
(66.6)
31
(33.3)
2+ 21
(80.8%)
5 (19.2%) 17
(60.7%)
11
(39.3%)
3+ 51 (79.7%) 13 (20.3%) 37
(45.1%)
45
(54.9%)
Two different AP-2 antibodies were used; one recognised AP-2α and β isoforms while the other recognised only the AP-2α isoform. Significance 
level P = 0.05.
adjacent stromal tissue. Our findings and those of others [40]
support this in showing increased frequency of AP-2 expres-
sion in lobular type breast cancers, generally regarded in hav-
ing good prognosis. However, our data showed that the AP-
2α/β marker was not found to have prognostic independence
Prior to targeting AP-2 for therapeutic benefit further work is
needed to better characterise the function of the AP-2 gene
family because of conflicting data concerning its association
with tumour development. For instance, the anti-inflammatory
drug tolfenamic acid has been shown to inhibit AP-2 and YY1
and in turn this has been shown to down-regulate HER2
mRNA expression [15]. In contrast, our data suggest that the
neutralisation of AP-2 and YY1 would have negligible impact
on the treatment of HER2 over-expressers and at worst, could
actually negate the tumour suppressing benefits of AP-2 as
reported by ourselves and others [31,32,35,39].
Conclusions
Approximately 2% of breast cancer patients express discord-
ant HER2 protein expression independently of HER2 gene
amplification. We found that expression of the transcription
factors AP-2 and YY1 associated with this in only 0.32% of
the entire study group. Further studies are required to deter-
mine the response of patients to anti-HER2 therapy when pre-
senting with discordant HER2 gene and protein expression. In
support of previous studies, we found that AP-2 and YY-1 cor-Breast Cancer Research    Vol 11 No 6    Powe et al.
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Table 6
Association between YY1 nuclear protein expression with HER-2 gene and protein expression levels
YY1
Negative Positive χ2 P-value
HER-2 Gene Expression Normal 315 (40.6%) 190 (49.4%) 13.115 0.004
Amplified 68 (8.8%) 16 (4.2%)
Gain 13 (1.7%) 7 (1.8%)
HER-2 Protein Expression 0 366 (67.3%) 178 (32.7%) 19.882 <0.001
1+ 13 (39.4%) 20 (60.6%)
2+ 21 (4.7%) 7 (3.3%)
3+ 51 (11.3%) 10 (4.7%)
Significance level P = 0.05.
relate with good clinical outcome in patients with breast
cancer.
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